What Changed? The FDA’s Clarification on Compounded GLP-1 Drugs
In late April 2025, the FDA issued a key update regarding the use of compounded GLP-1 receptor agonists like semaglutide and tirzepatide. The central message is that the agency is tightening oversight now that it is reporting that the national […]
What Changed? The FDA’s Clarification on Compounded GLP-1 Drugs Read More »
